metformin has been researched along with Experimental Mammary Neoplasms in 21 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An efficacious metformin dose for breast cancer varies among tumour subtypes based on cation transporter expression, which provides a useful guide for dose selection." | 7.91 | Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours. ( Cai, H; Everett, RS; Thakker, DR, 2019) |
| "The antidiabetic drug metformin exerts antineoplastic effects against breast cancer and other cancers." | 7.83 | Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells. ( Cai, H; Everett, RS; Han, TK; Thakker, DR; Zhang, Y, 2016) |
| "The development and induction of the carcinogenesis process in the different rat models with the high-fat diet impact were also accompanied by initiation of free-radical oxidation processes, which we studied at the initial (estimated by the level of diene conjugates) and final (TBARS products) stages of this process." | 5.72 | Effects of melatonin and metformin in preventing lysosome-induced autophagy and oxidative stress in rat models of carcinogenesis and the impact of high-fat diet. ( Kurhaluk, N; Tkachenko, H, 2022) |
| "Metformin (MET) is a well-known anti-diabetic drug that also has anti-cancer effects." | 5.72 | MPEG-PCL Nanomicelles Platform for Synergistic Metformin and Chrysin Delivery to Breast Cancer in Mice. ( Chang, J; He, M; Li, Y; Luo, D; Luo, Y; Ran, L; Wang, H; Wang, X; Zhao, C; Zhong, X, 2022) |
| "An efficacious metformin dose for breast cancer varies among tumour subtypes based on cation transporter expression, which provides a useful guide for dose selection." | 3.91 | Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours. ( Cai, H; Everett, RS; Thakker, DR, 2019) |
| "The antidiabetic drug metformin exerts antineoplastic effects against breast cancer and other cancers." | 3.83 | Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells. ( Cai, H; Everett, RS; Han, TK; Thakker, DR; Zhang, Y, 2016) |
| "Our data allow us to suggest that metformin, reducing the stimulatory effect of obesity on tumor development, has a potential role in the management of cancers." | 3.81 | Metformin reduces the Walker-256 tumor development in obese-MSG rats via AMPK and FOXO3a. ( Akamine, EH; de Carvalho, MH; de Queiroz, EA; Fortes, ZB; Sampaio, SC, 2015) |
| "The efficacy of metformin alone and in combination with tamoxifen against ER-positive breast cancer was analyzed by cell survival, DNA replication activity, plate colony formation, soft-agar, flow cytometry, immunohistochemistry, and nude mice model assays." | 3.80 | Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. ( Chen, S; Guo, Y; Lai, X; Liu, W; Ma, J; Wei, Y; Xue, Y; Yu, S; Zhang, J; Zhang, Y; Zhong, C, 2014) |
| "The development and induction of the carcinogenesis process in the different rat models with the high-fat diet impact were also accompanied by initiation of free-radical oxidation processes, which we studied at the initial (estimated by the level of diene conjugates) and final (TBARS products) stages of this process." | 1.72 | Effects of melatonin and metformin in preventing lysosome-induced autophagy and oxidative stress in rat models of carcinogenesis and the impact of high-fat diet. ( Kurhaluk, N; Tkachenko, H, 2022) |
| "Metformin (MET) is a well-known anti-diabetic drug that also has anti-cancer effects." | 1.72 | MPEG-PCL Nanomicelles Platform for Synergistic Metformin and Chrysin Delivery to Breast Cancer in Mice. ( Chang, J; He, M; Li, Y; Luo, D; Luo, Y; Ran, L; Wang, H; Wang, X; Zhao, C; Zhong, X, 2022) |
| "Melatonin caused an increase in total antioxidant status and a substantial reduction in ROS as estimated from aldehyde and ketone derivatives, lipid peroxidation at the initial (diene conjugates) and terminal stages (TBARS), and increased catalase and glutathione peroxidase activities." | 1.48 | Melatonin and Metformin Diminish Oxidative Stress in Heart Tissue in a Rat Model of High Fat Diet and Mammary Carcinogenesis. ( Bojkova, B; Demkow, U; Kurhaluk, N; Kyriienko, S; Radkowski, M; Winklewski, PJ; Zaitseva, OV, 2018) |
| "Metformin was administered by gavage or in the diet, at a human equivalent dose, in standard mammary cancer models: (i) methylnitrosourea (MNU)-induced estrogen receptor-positive (ER(+)) mammary cancers in rats, and (ii) MMTV-Neu/p53KO ER(-) (estrogen receptor-negative) mammary cancers in mice." | 1.42 | Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models. ( Bennett, C; Bernard, PS; Bode, AM; Green, JE; Grubbs, CJ; Juliana, MM; Lubet, RA; McGovern, R; Moeinpour, F; Reid, JM; Steele, VE; Stijleman, IJ; Thompson, MD, 2015) |
| "Metformin is a widely prescribed drug for the treatment of type II diabetes." | 1.42 | Effects of metformin, buformin, and phenformin on the post-initiation stage of chemically induced mammary carcinogenesis in the rat. ( Echeverria, D; Jiang, W; McGinley, JN; Thompson, HJ; Thompson, MD; Zhu, Z, 2015) |
| "Metformin is an oral biguanide used for type II diabetes." | 1.40 | Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. ( Bachman, N; Blackwelder, AJ; Davis, M; Edgerton, S; Liu, B; Thor, AD; Williams, LL; Yang, X; Zhu, P, 2014) |
| "Metformin was administered in drinking water (at a concentration of 50 microg/ml and 500 microg/ml) 13 days before the first NMU dose until the termination of the experiment." | 1.35 | Metformin in chemically-induced mammary carcinogenesis in rats. ( Ahlers, I; Ahlersova, E; Bojkova, B; Garajova, M; Kassayova, M; Kutna, V; Orendas, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 4 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Kurhaluk, N | 2 |
| Tkachenko, H | 1 |
| Lee, JO | 1 |
| Kang, MJ | 1 |
| Byun, WS | 1 |
| Kim, SA | 1 |
| Seo, IH | 1 |
| Han, JA | 1 |
| Moon, JW | 1 |
| Kim, JH | 1 |
| Kim, SJ | 1 |
| Lee, EJ | 1 |
| In Park, S | 1 |
| Park, SH | 1 |
| Kim, HS | 1 |
| Salim, E | 1 |
| El-Sisi, AE | 2 |
| Sokar, S | 1 |
| El-Sayad, M | 1 |
| Moussa, E | 1 |
| Sun, Y | 1 |
| Liu, L | 1 |
| Zhou, L | 1 |
| Yu, S | 2 |
| Lan, Y | 1 |
| Liang, Q | 1 |
| Liu, J | 1 |
| Cao, A | 1 |
| Liu, Y | 1 |
| Luo, D | 1 |
| Wang, X | 1 |
| Zhong, X | 1 |
| Chang, J | 1 |
| He, M | 1 |
| Wang, H | 1 |
| Li, Y | 1 |
| Zhao, C | 1 |
| Luo, Y | 1 |
| Ran, L | 1 |
| Bojkova, B | 3 |
| Radkowski, M | 1 |
| Zaitseva, OV | 1 |
| Kyriienko, S | 1 |
| Demkow, U | 1 |
| Winklewski, PJ | 1 |
| Kajo, K | 1 |
| Kubatka, P | 1 |
| Solár, P | 1 |
| Péč, M | 1 |
| Adamkov, M | 1 |
| Sokar, SS | 1 |
| El-Sayad, ME | 1 |
| Moussa, EA | 1 |
| Salim, EI | 1 |
| Cai, H | 2 |
| Everett, RS | 2 |
| Thakker, DR | 2 |
| Shehata, M | 1 |
| Kim, H | 1 |
| Vellanki, R | 1 |
| Waterhouse, PD | 1 |
| Mahendralingam, M | 1 |
| Casey, AE | 1 |
| Koritzinsky, M | 1 |
| Khokha, R | 1 |
| Zhu, P | 1 |
| Davis, M | 1 |
| Blackwelder, AJ | 1 |
| Bachman, N | 1 |
| Liu, B | 1 |
| Edgerton, S | 1 |
| Williams, LL | 1 |
| Thor, AD | 1 |
| Yang, X | 1 |
| Ma, J | 1 |
| Guo, Y | 1 |
| Chen, S | 1 |
| Zhong, C | 1 |
| Xue, Y | 1 |
| Zhang, Y | 2 |
| Lai, X | 1 |
| Wei, Y | 1 |
| Zhang, J | 1 |
| Liu, W | 1 |
| de Queiroz, EA | 1 |
| Akamine, EH | 1 |
| de Carvalho, MH | 1 |
| Sampaio, SC | 1 |
| Fortes, ZB | 1 |
| Thompson, MD | 2 |
| Grubbs, CJ | 1 |
| Bode, AM | 1 |
| Reid, JM | 1 |
| McGovern, R | 1 |
| Bernard, PS | 1 |
| Stijleman, IJ | 1 |
| Green, JE | 1 |
| Bennett, C | 1 |
| Juliana, MM | 1 |
| Moeinpour, F | 1 |
| Steele, VE | 1 |
| Lubet, RA | 1 |
| Zhu, Z | 1 |
| Jiang, W | 1 |
| Echeverria, D | 1 |
| McGinley, JN | 1 |
| Thompson, HJ | 1 |
| Gao, S | 1 |
| Jiang, J | 1 |
| Li, P | 1 |
| Song, H | 1 |
| Wang, W | 1 |
| Li, C | 1 |
| Kong, D | 1 |
| Han, TK | 1 |
| Curry, A | 1 |
| Khatri, I | 1 |
| Kos, O | 1 |
| Zhu, F | 1 |
| Gorczynski, R | 1 |
| Orendas, P | 1 |
| Garajova, M | 1 |
| Kassayova, M | 1 |
| Kutna, V | 1 |
| Ahlersova, E | 1 |
| Ahlers, I | 1 |
| Rigla Cros, M | 1 |
| Anisimov, VN | 1 |
| Egormin, PA | 1 |
| Bershtein, LM | 1 |
| Zabezhinskii, MA | 1 |
| Piskunova, TS | 1 |
| Popovich, IG | 1 |
| Semenchenko, AV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer[NCT01589367] | Phase 2 | 208 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 other studies available for metformin and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Effects of melatonin and metformin in preventing lysosome-induced autophagy and oxidative stress in rat models of carcinogenesis and the impact of high-fat diet.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Autophagy; Carcinogenesis; Diet, High-Fat; Female; Humans | 2022 |
Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2019 |
Metformin potentiates the chemotherapeutic effects of doxorubicin on 2-amino-1-methyl-6-phenylimidazo[4,5b] pyridine-induced Mammary Carcinoma in rats.
Topics: Animals; Antibiotics, Antineoplastic; Doxorubicin; Drug Synergism; Female; Hypoglycemic Agents; Imid | 2021 |
Tumor Microenvironment-Triggered Charge Reversal Polymetformin-Based Nanosystem Co-Delivered Doxorubicin and IL-12 Cytokine Gene for Chemo-Gene Combination Therapy on Metastatic Breast Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Combined Modality T | 2020 |
MPEG-PCL Nanomicelles Platform for Synergistic Metformin and Chrysin Delivery to Breast Cancer in Mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose | 2022 |
Melatonin and Metformin Diminish Oxidative Stress in Heart Tissue in a Rat Model of High Fat Diet and Mammary Carcinogenesis.
Topics: Animals; Antioxidants; Catalase; Diet, High-Fat; Female; Glutathione Peroxidase; Heart; Lipid Peroxi | 2018 |
Metformin and melatonin improve histopathological outcome of NMU-induced mammary tumors in rats.
Topics: Animals; Cell Proliferation; Diet, High-Fat; Female; Mammary Neoplasms, Experimental; Melatonin; Met | 2019 |
Anticancer effect of metformin against 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine-induced rat mammary carcinogenesis is through AMPK pathway and modulation of oxidative stress markers.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Carcinogenesis; Carcinogens; Choleste | 2019 |
Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2019 |
Identifying the murine mammary cell target of metformin exposure.
Topics: Animals; Apoptosis; Cell Cycle; Cell Lineage; Cell Separation; DNA Damage; Female; Flow Cytometry; H | 2019 |
Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.
Topics: Animals; Cells, Cultured; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Int | 2014 |
Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Ne | 2014 |
Metformin reduces the Walker-256 tumor development in obese-MSG rats via AMPK and FOXO3a.
Topics: Animals; Carcinoma 256, Walker; Cyclic AMP-Dependent Protein Kinases; Female; Food Additives; Forkhe | 2015 |
Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models.
Topics: Alkylating Agents; Animals; Biomarkers, Tumor; Disease Models, Animal; Female; Humans; Hypoglycemic | 2015 |
Effects of metformin, buformin, and phenformin on the post-initiation stage of chemically induced mammary carcinogenesis in the rat.
Topics: Animals; Apoptosis; Blotting, Western; Buformin; Carcinogens; Cell Proliferation; Cell Transformatio | 2015 |
Attenuating tumour angiogenesis: a preventive role of metformin against breast cancer.
Topics: Animals; Breast Neoplasms; Female; HeLa Cells; Humans; Hypoglycemic Agents; Mammary Neoplasms, Exper | 2015 |
Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; C | 2016 |
Importance of CD200 expression by tumor or host cells to regulation of immunotherapy in a mouse breast cancer model.
Topics: Animals; Antibodies, Neoplasm; Antigens, CD; Autophagy; Breast Neoplasms; Cell Line, Tumor; Female; | 2017 |
Metformin in chemically-induced mammary carcinogenesis in rats.
Topics: Animals; Anticarcinogenic Agents; Drinking; Eating; Female; Hydrocortisone; Insulin-Like Growth Fact | 2009 |
[Glargine insulin and cancer risk].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Diabetes Complications; Diabe | 2009 |
Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice.
Topics: Adenocarcinoma; Animals; Female; Homozygote; Hypoglycemic Agents; Longevity; Mammary Neoplasms, Anim | 2005 |